Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells $220,974.75 in Stock

Key Points

• DexCom EVP Sadie Stern sold 2,565 shares for approximately $220,975 at an average price of $86.15, reducing her holdings by 2.04% to 123,478 shares. The transaction was made under a pre-arranged Rule 10b5-1 trading plan.
• DexCom shares recently traded near $86.29, while analysts maintain a “Moderate Buy” consensus with an average price target of $89.08 and targets ranging as high as $105.
• The company reported quarterly revenue of $1.31 billion and adjusted earnings of $0.70 per share, beating estimates and representing 13.1% year-over-year revenue growth; institutional investors own 97.75% of the stock.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Sadie Stern sold 2,565 shares of DexCom stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of $86.15, for a total value of $220,974.75. Following the completion of the sale, the executive vice president owned 123,478 shares in the company, valued at approximately $10,637,629.70. This represents a 2.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sadie Stern also recently made the following trade(s):

• On Thursday, August 27th, Sadie Stern sold 2,565 shares of DexCom stock. The shares were sold at an average price of $88.37, for a total value of $226,669.05.

DexCom Trading Down 0.4%

DXCM stock traded down $0.35 on Wednesday, reaching $86.29. The company's stock had a trading volume of 3,403,851 shares, compared to its average volume of 5,087,884. The business has a fifty day simple moving average of $85.81 and a two-hundred day simple moving average of $74.17. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $92.59. The firm has a market cap of $32.56 billion, a PE ratio of 34.11, a PEG ratio of 1.45 and a beta of 1.42. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. During the same period in the previous year, the firm earned $0.48 EPS. The company's quarterly revenue was up 13.1% compared to the same quarter last year. As a group, research analysts forecast that DexCom, Inc. will post 2.64 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Stifel Nicolaus set a $95.00 price objective on shares of DexCom and gave the company a "buy" rating in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft started coverage on DexCom in a research report on Tuesday, June 23rd. They issued a "buy" rating and a $86.00 target price on the stock. Mizuho raised their price objective on shares of DexCom from $90.00 to $95.00 and gave the stock an "outperform" rating in a report on Friday, July 31st. Wells Fargo & Company boosted their target price on shares of DexCom from $85.00 to $90.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. Finally, Robert W. Baird set a $105.00 target price on shares of DexCom in a report on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $89.08.

Institutional Trading of DexCom

A number of large investors have recently made changes to their positions in DXCM. QRG Capital Management Inc. raised its holdings in shares of DexCom by 5.3% in the second quarter. QRG Capital Management Inc. now owns 31,772 shares of the medical device company's stock worth $2,140,000 after buying an additional 1,586 shares during the period. Sequoia Financial Advisors LLC lifted its position in shares of DexCom by 15.1% during the second quarter. Sequoia Financial Advisors LLC now owns 19,116 shares of the medical device company's stock worth $1,287,000 after purchasing an additional 2,509 shares during the last quarter. Tidal Investments LLC lifted its position in shares of DexCom by 6.5% during the second quarter. Tidal Investments LLC now owns 65,922 shares of the medical device company's stock worth $4,440,000 after purchasing an additional 3,995 shares during the last quarter. Van Hulzen Asset Management LLC purchased a new stake in shares of DexCom during the second quarter valued at $230,000. Finally, Scholtz & Company LLC boosted its stake in shares of DexCom by 12.7% during the second quarter. Scholtz & Company LLC now owns 77,334 shares of the medical device company's stock valued at $5,208,000 after purchasing an additional 8,686 shares during the period. 97.75% of the stock is currently owned by institutional investors.

DexCom Company Profile

DexCom, Inc NASDAQ: DXCM develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its technology uses a small wearable sensor to measure glucose levels continuously and transmit readings to a compatible receiver, smartphone or other connected device, helping users monitor glucose trends and make more informed treatment and lifestyle decisions.

The company's product portfolio includes the Dexcom G7 and Dexcom G6 real-time CGM systems, as well as related software and digital health tools such as Dexcom Clarity for glucose data analysis and reporting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.